LocalMed in licensing talks for PerfusaSleeve angioplasty perfusion technology.
This article was originally published in The Gray Sheet
Executive Summary
LOCALMED PERFUSASLEEVE OFFERS LOWER-COST PERFUSION CATHETER than devices sold by market leader Advanced Cardiovascular Systems, LocalMed President and CEO Paul Goeld told investors at the recent UBS Securities life sciences conference in New York City. "The advantage of [PerfusaSleeve] is that we preserve the operator's choice of using high performance, low cost" percutaneous transluminal coronary angioplasty balloons. "In fact, the cost of our perfusion device along with the standard PTCA balloon is still far less than the cost of the perfusion balloon from ACS," Goeld claimed.